RBC Capital Maintains Outperform on Xenon Pharmaceuticals, Raises Price Target to $56
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Brian Abrahams has maintained an Outperform rating on Xenon Pharmaceuticals (NASDAQ:XENE) and increased the price target from $51 to $56.
November 28, 2023 | 9:31 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
RBC Capital analyst Brian Abrahams has reaffirmed an Outperform rating on Xenon Pharmaceuticals and raised the price target from $51 to $56, indicating a positive outlook on the stock.
The increase in price target by RBC Capital suggests a strong conviction in the future performance of Xenon Pharmaceuticals. This endorsement from a reputable analyst is likely to instill confidence in investors and could lead to a short-term increase in the stock price, as market participants may adjust their valuations to align with the new price target.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100